Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.42 | N/A | -7.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.42 | N/A | -7.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions affecting performance. They did not provide any forward guidance, indicating uncertainty.
Management noted challenges in meeting EPS expectations.
There was no guidance provided for future quarters.
Pfizer's earnings report showed a miss on EPS, which contributed to a 2.26% decline in stock price. The lack of revenue data and forward guidance adds to investor uncertainty. Overall, the company faces challenges that may impact its performance in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Feb 1, 2021